Peroxisome proliferator-activated receptors (PPARs) are ligandactivated transcription factors that are originally reported to regulate the expression of genes involved in fatty acid uptake and oxidation, lipid metabolism and inflammation. 1 The PPARs consist of three subtypes, PPARa, PPARb/d (PPARb) and PPARg; PPARa is expressed primarily in the liver, brown adipose tissue, kidney, heart and skeletal muscle, PPARg is expressed mainly in white and brown adipose tissue, and PPARb is ubiquitously expressed; PPAR(s) have recently been reported to be involved in tumorigenicity. 2 As for the inflammation, PPARs are considered to be anti-inflammatory, and PPAR agonists induce the downregulation of nuclear factor-kappa B (NF-kB) activity. As the constitutive higher activation of NF-kB is considered to be important for the survival and proliferation in B-cell malignancies, including multiple myeloma (MM), it has been extensively explored as to which compounds can inhibit NF-kB activity in the MM. 3 In this paper, we first examined which subtype of PPAR was expressed in myeloma cells and whether PPAR activation could inhibit the proliferation of myeloma cells in vitro. Primary myeloma cells from newly diagnosed MM patients as well as myeloma cell lines (U266, ILKM2, ILKM3, ILKM8, AMO1, NOP2 and KMS5) predominantly expressed the PPARb gene and also showed the weak expression of PPARg1 (Figure 1a) . We also found the suppressive effect of carbacyclin (PPARb agonist) or troglitazone (PPARg agonist), but not Wy14643 (PPARa agonist) on primary myeloma cells as well as myeloma cell lines, as shown in Figure 1b and c.
Although myeloma cells predominantly expressed PPARb, we evaluated which compounds showed PPARb-stimulating activity in the PPREb-luciferase assay. 4 We screened the PPARbstimulating activity of prostaglandins, hydroxy-eicosatetraenoic acids (HETEs), the hormones of the adrenal cortex, derivatives of cholesterol and flavonoids. Among the compounds we examined, interestingly, the hormones of the adrenal cortex, dehydroepiandrosterone sulfate DHEA-S and hydrocortisone (dexamethasone (Dex)), showed the strong PPARb-stimulating activity (Figure 2a) , and one of the flavonoids from Scutellaria radix, baicalein, 5 also showed strong PPARb-stimulating activity (Figure 2b ). Furthermore, we found the cooperative effect of Dex and baicalein on the PPARb-stimulating activity in the PPREbluciferase assay (Figure 2c ). We examined whether Dex and baicalein showed the cooperative effect on the expression of PPAR response element (PPRE)-mediated target genes, ILK and PPARg1 in myeloma cell lines (U266 and ILKM2) by reverse Letters to the Editor transcriptase-polymerase chain reaction (RT-PCR). We confirmed that combination of Dex and baicalein cooperatively augmented the expression of ILK and PPARg1 mRNA in U266 and ILKM2 cells.
We examined whether Dex and baicalein showed a cooperative effect on the growth suppression in primary myeloma cells, as well as myeloma cell lines (U266, NOP2 and ILKM2 cells). In the U266 cells that were resistant to Dex, the combination of Dex with baicalein showed a cooperative effect on the growth suppression, and in NOP2 and ILKM2 cells that were sensitive to Dex, the combination of Dex with baicalein also showed a cooperative effect on their growth suppression. This cooperative effect of Dex and baicalein was also found in primary myeloma cells; two representative cases are presented in Figure 3 . In the MM1 case, the combination of Dex (10 mM) with baicalein (10 mM) induced marked growth suppression of MPC-1 þ mature and MPC-1 À immature myeloma cells, 6 whereas the combination of Dex with baicalein * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Figure 3 Cooperative growth suppression of baicalein and Dex in primary myeloma cells. Bone marrow mononuclear cells (BMMNC) from overt myelomas (MM1 and MM2) were cultured with baicalein (10 mM) and/or Dex (10 mM) for 3 or 6 days. After the culture, the cells were harvested, stained with FITC-anti-CD38, PE-anti-MPC-1 and PC5-anti-CD45 antibodies and applied to a flow cytometer. Viable cell numbers of n Po0.05, nn Po0.01.
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showed the marked growth suppression of MPC-1 À immature myeloma cells, but not MPC-1 þ mature myeloma cells in the MM2 case. In the primary myeloma cells from 20 cases, we summarized that the combination of Dex with baicalein showed consistent growth suppression in MPC-1 À immature myeloma cells from all cases, and MPC-1 þ mature myeloma cells were significantly suppressed in seven out of 20 cases.
The ligand-induced activation of PPARb is reported to suppress the NF-kB activity. Two possible mechanisms for its downregulation of NF-kB activity were reported: one was the upregulation of IkB gene expression 7 and the other was the inhibitory physical interaction between the p65 subunit of NF-kB and PPAR in the nucleus. 8 We examined whether PPARb interacted with the p65 of NF-kB after IL-1a stimulation by the immunoprecipitation followed by Western blotting. Costimulation of IL-1a with Dex and baicalein strongly enhanced the physical interaction between p65 of NF-kB and PPARb (data not shown). The binding activity of NF-kB (p65/p50) to the kB site was also suppressed in the treatment with Dex and baicalein. Furthermore, the expression of the NF-kB target genes, such as IL-6 and IkBa, was markedly reduced by the treatment of Dex and baicalein combined with IL-1a stimulation in U266 cells.
With regard to the therapeutic aspect, the cooperative growth suppression of Dex and baicalein in myeloma cells might be useful for myeloma therapy. Combinatory treatment with both may overcome the Dex resistance and the baicalein resistance in primary myeloma cells, as well as myeloma cell lines. It is possible that baicalein combined with Dex can induce the activation of PPARb and glucocorticoid receptor (GR), which cooperatively suppress the transcriptional activity of NF-kB in the nucleus of myeloma cells. Clinical trials would rapidly evaluate the utility of this combinatory treatment in relapsed and refractory myeloma cases.
Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy Constitutive activation of platelet-derived growth factor receptor (PDGFR) is one of the features of myeloproliferative disease (MPD).
1 PDGFR is a member of type III receptor tyrosine kinase that transmits mitotic signals in cells of mesenchymal origin. Both PDGFRA and PDGFRB genes, located on chromosomes 4q12 and 5q33 respectively, form fusion gene as a result of chromosome translocation. Representative examples are TEL-PDGFRB in t(5;12)(q33;p13) 2 and FIP1L1-PDGFRA in del(4)(q12), 3 both of the gene products known to have ligandindependent kinase activity. The former is observed in chronic myelomonocytic leukaemia (CMMoL) as well as other MPDs with eosinophilia, whereas the latter has been reported in hypereosinophilic syndrome (HES).
We report here a case of chronic idiopathic myelofibrosis (CIMF) with t(5;12)(q33;p13), which transformed to acute myelogenous leukaemia (AML). This case is unique in two aspects: (1) this is the first report of CIMF with TEL-PDGFRB fusion and (2) a novel type of TEL-PDGFRB fusion transcript that retained the internal and ETS domains of TEL was expressed. The leukaemic cells responded well to a series of chemotherapy, which was followed by administration of imatinib mesylate, a kinase inhibitor for both PDGFR and ABL. It gave a partial cytogenetic response but failed to maintain a remission of leukaemia. This case implies the existence of various types of TEL-PDGFRB fusion gene with possible impact on the phenotype of the disease.
A 37-year-old male presented with nasal and gingival bleeding in August 2005. He showed marked hepatosplenomegaly at presentation: spleen was palpable 10 cm below the left
